<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046539</url>
  </required_header>
  <id_info>
    <org_study_id>ALK33-008</org_study_id>
    <nct_id>NCT01046539</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacodynamics of RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      This is a single site, double-blind, randomized, placebo-controlled, crossover study to
      assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy,
      opioid-experienced, non-treatment-seeking subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics (PD) of study drug</measure>
    <time_frame>24 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS Scores</measure>
    <time_frame>24 Hours period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupuillometry Assessments</measure>
    <time_frame>24 Hour Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Symptoms</measure>
    <time_frame>15 min pre and post nal, 3 hrs post bup admin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine pharmacokinetics (PK) and evaluate safety and tolerability of study drug</measure>
    <time_frame>24 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max plasma concentration</measure>
    <time_frame>24 Hour Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration</measure>
    <time_frame>24 Hour Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve (AUC)</measure>
    <time_frame>24 Hour Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional PK parameters may be analyzed</measure>
    <time_frame>As appropriate</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>RDC-0313 + Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDC-0313 + Buprenorphine</intervention_name>
    <description>1 and 4 mg (1 dose for each) + 8 mg</description>
    <arm_group_label>RDC-0313 + Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be capable of understanding and complying with the protocol and has
             signed the informed consent

          -  Must be 18-55 years of age

          -  Must have a body mass index of 18.0-30.0 kg/m2 at screening

          -  Female subjects must agree to use an acceptable method of contraception from date of
             consent and until two weeks after the last dose

          -  Subjects must be willing not to use alcohol-, tobacco, caffeine-, or
             xanthine-containing products while resident at inpatient facility

          -  Subjects must be an experienced opioid user who meets the following criteria: 1) has
             used opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least
             10 occasions in the past five years; 2) has used opioids at least 2 times in the two
             years prior to screening; and 3) is not physically dependent on opioids, as assessed
             by medical history and naloxone challenge performed at screening

        Exclusion Criteria:

          -  Must not have any current or piror significant hepatic, renal, endocrine, cardiac,
             nervous, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic
             disorders.

          -  Must not have current or past opioid, alcohol, or other durg dependence (excluding
             nicotine and caffeine) or showing signs of withdrawal following the naloxone (Narcan)
             challenge.

          -  Please contact site for additional information about other exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Langley Porter Psychiatric Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <name_title>Reese Jones, M.D. / Principal Investigator</name_title>
    <organization>Langley Porter Psychiatric Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>ALKS-33</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

